Our goal is to create smart materials that help the body repair itself. Our first target is bone repair. Our plans extend to the repair of any tissue.
Our first generation of materials is based on tough ceramics which accelerate bone tissue growth.
Our second generation of materials is designed to promote tissue healing wherever it is needed.
BioCeramic Therapeutics Ltd received its first financing round in the first quarter of 2007. This funding will enable the company to press forward with its plans to develop a range of products designed to help patients suffering from a range of bone and soft tissue related conditions.
Read about our technologies and people to find out more, or contact us directly.
Our Technologies
Materials based on glass with components that make it more bone-like have been implanted in patients since the 1970s. Our founding scientists have shown that a modification to such bioactive ceramics accelerates the deposition of the required bone-related mineral (hydroxyapatite). The modification simultaneously promotes bone growth and inhibits bone destruction.
The second generation of smart materials mimics the natural structure of the frameworks that surrounds the cells in your body. This nanostructured material can prompt tissue regeneration by virtue of its physical as well as chemical properties.
Who we benefit
The 20th century saw life expectancy increase by at least a decade. In the 21st century, one of the challenges will be ensuring that we are physically and mentally able to thrive as we age. This is the task of regenerative medicine.
BioCeramic Therapeutics is dedicated to developing medical interventions that enable the body to renew damaged tissues. We have new materials that promise faster recovery from fractures, building stronger bones rather than scar tissue.Our materials also have many other potential applications.
This is the challenge that faces us. Taking it on promises longer and more active lives.
People
Daniel Green, CEO
Daniel is an experienced life sciences investor and entrepreneur. He co-founded Gendaq Ltd in 1998, and has worked in senior roles for life sciences investment funds HBM Partners (Zurich, Switzerland), Dresdner Kleinwort, and MVM (both London, UK) and other funds. He has served on many company boards, in the US, UK and France.
Molly Stevens, CSO
Molly is Reader in Regenerative Medicine and Nanotechnology at the Department of Materials, Imperial College London, UK. She joined Imperial in 2004 from Professor Robert Langer laboratory in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT). Prior to this she graduated from Bath University with a first class honours degree in Pharmaceutical Sciences and a PhD from the University of Nottingham. In 2005 she was awarded the prestigious Philip Leverhulme Prize among many other prizes and awards.
Robert Hill, Founding Scientist
Robert is Professor in Biomaterials at the Department of Materials, Imperial College London, UK. He has won many awards and academic distinctions and is the developer of a commercially successful material used in dentistry.
Board of Directors
Ribbit buy, try to change domains, buy domain domain frog. Main always in the name of his own tail?
The annual NSA Convention/Trade Fair attracts members from all over the world, as well as many photographica dealers, photo historians, and experts in various state-of-the-art applications of stereo imaging. Each convention features stereo projection programs, National Stereoscopic Association competitive exhibitions, an auction of fine photographica, and a large sales floor packed with images and equipment both antique and modern.
自然言語と同様、統語論（構文）規則と意味論規則で定義される。通常、それらを示した文書で仕様が示されるが、公式の実装だけで定義される言語もある。プログラミング言語は、情報を組織し処理するタスクについての理解を容易にし、アルゴリズムを正確に表現する。場合によっては、あらゆるアルゴリズムを記述できる言語だけを「プログラミング言語」と定義することもある。そこまでの機能のない人工言語を「コンピュータ言語」と呼ぶこともある。また、プログラミングへの応用も想定して設計されたロジバンのように、人間言語とコンピュータ言語の中間に位置するものがある。